Clinical Trials Logo

Clinical Trial Summary

This open label, Phase 1 study is to investigate the relative bioavailability of ABT-333 when delivered within different sites of the gastrointestinal tract in 12 healthy subjects.


Clinical Trial Description

Bioavailability of ABT-333 in different areas of the gut ;


Study Design

Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


NCT number NCT02052349
Study type Interventional
Source AbbVie
Contact
Status Completed
Phase Phase 1
Start date November 2013
Completion date December 2013

See also
  Status Clinical Trial Phase
Completed NCT01911741 - A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects Phase 1
Active, not recruiting NCT03154840 - Relative Bioavailability Among Different Eutropin Formulations Phase 1
Completed NCT04814472 - Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations Phase 1
Completed NCT03934333 - A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS) Phase 1
Not yet recruiting NCT06025318 - An Evaluation of the Effect of Food on the PK of a Novel PanCytoVirâ„¢ Suspension (100mg/ml), in Healthy, Adult Volunteers Phase 1
Not yet recruiting NCT06025344 - A Relative Bioavailability Study With a Novel PanCytoVirâ„¢ Oral Suspension (100 mg/ml) Phase 1
Completed NCT04686669 - A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations Phase 1
Completed NCT03483259 - To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers Phase 1
Completed NCT05296382 - Bioavailability of Tebipenem (SPR994) Crushed Tablet Phase 1